Haemostatic Disorders
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr. Esra Gülderen discusses her path into hematology, the critical role of mentorship, and how early research experiences shaped her confidence. Now a Co-chair of the EBMT Trainee Committee, she shares what motivates her and why clear communication, curiosity, and resilience are essential traits for aspiring haematologists.
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
The International Society on Thrombosis and Haemostasis (ISTH) has issued an evidence-based clinical practice guideline aimed at revolutionizing the treatment landscape for congenital haemophilia A and B. Hemophilia, a rare bleeding disorder caused by deficiencies in blood coagulation factors, affects individuals worldwide and demands intricate management strategies.
The Phase 3 BASIS trial assessed the efficacy and safety of marstacimab, a monoclonal antibody targeting the tissue factor pathway inhibitor, in participants with severe haemophilia A or moderately severe to severe haemophilia B without inhibitors. The study demonstrated marstacimab's effectiveness ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
